The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

ConditionBiliary Tract Neoplasms

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorThe Second Affiliated Hospital of Shandong First Medical University

About this trial

Evaluate the progression-free survival (PFS) of benmelstobart combined with gemcitabine and cisplatin in first-line patients with advanced cholangiocarcinoma, and the progression-free survival (PFS) of benmelstobart combined with anlotinib in second-line patients with advanced cholangiocarcinoma.

Eligibility criteria

Qualifiers

Hemoglobin (HB) ≥90 g/L (without blood transfusion within 14 days prior).

Absolute neutrophil count (ANC) ≥1.5×10⁹/L.

Platelet count (PLT) ≥80×10⁹/L.

Albumin (ALB) ≥30 g/L (without albumin transfusion within 14 days prior).

Disqualifiers

None

Trial design

Treatments tested in this trial

Benmelstobart combined with gemcitabine and cisplatin

Treatment groups

30 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

The Second Affiliated Hospital of Shandong First Medical University

Lead sponsor

Source ClinicalTrials.gov